Immutep reports strong cancer trial results
Immutep (ASX:IMM) has made significant progress over the past year with its lead immunotherapy candidate, eftilagimod alpha (efti).
Read More
Immutep Limited
Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease.
The company are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response.
Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders.
Corporate Connect Research Report
DOWNLOAD RESEARCH
DOWNLOAD RESEARCH
Spotlight Videos
Immutep (ASX:IMM) announces positive results in head and neck cancer treatment
Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the company's latest results in head and neck cancer.
WATCH VIDEOAll Immutep Limited Content
News
Immutep (ASX:IMM) announces positive results in head and neck cancer treatment
Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the company's latest results in head and neck cancer.
Read More
Stocks of the Hour: Immutep, Lepidico, Mithril Silver and Gold
A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), Lepidico (ASX:LPD) and Mithril Silver and Gold (ASX:MTH).
Read More
Immutep (ASX:IMM) reports first subject dosed in autoimmune disease study
Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress with the company's IMP761 drug, which is potentially active in more than 90% of autoimmune diseases.
Read More
Stocks of the Hour: Immutep, LiveHire, Forbidden Foods, Estrella Resources
A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), LiveHire (ASX:LVH), Forbidden Foods (ASX:FFF) and Estrella Resources (ASX:ESR).
Read More
